

Diese Meldung kann unter <http://www.presseportal.de/pm/38683/1675633/eans-news-epigenomics-ceo-to-give-corporate-update-at-investor-conferences-in-europe-and-u-s> abgerufen werden.



## EANS-News: Epigenomics CEO to give Corporate Update at Investor Conferences in Europe and U.S.

03.09.2010 - 11:01 Uhr, Epigenomics AG

-----  
Corporate news transmitted by euro adhoc. The issuer/originator is solely responsible for the content of this announcement.

----- Company Information/Molecular diagnostics

Press release, Berlin, Germany, and Seattle, WA, U.S.A., September 3, 2010 (euro adhoc) - Epigenomics AG (Frankfurt Prime Standard: ECX), a cancer molecular diagnostics company informed, that Geert W. Nygaard, CEO Epigenomics AG, will provide a corporate update at two upcoming Investor conferences in Zurich and New York.

At the German Healthcare Conference in Zurich and the UBS Global Life Sciences Conference in New York he will inform the investment community on the progress the Company made in commercializing its molecular diagnostic products for colon and lung cancer and provide an outlook on plans and activities regarding FDA clearance and commercialization of the Company's colorectal cancer blood test Epi proColon in the U.S.A.

### Conference Details:

German Healthcare Conference Presentation on September 8, 2010 at 3:45 p.m. CET (9:45 a.m. EDT), Zurich, Switzerland

UBS Global Life Sciences Conference Presentation on September 20, 2010, at 7:30 a.m. EDT (1:30 p.m. CET), New York, U.S.A.

The presentation will be available for download on Epigenomics website:  
[http://www.epigenomics.com/en/down\\_loads/corporate\\_material/](http://www.epigenomics.com/en/down_loads/corporate_material/)

For further question please contact:

Dr. Achim Plum Sen. VP. Corporate Development Tel. +49 30 24 34 5 386  
[achim.plum@epigenomics.com](mailto:achim.plum@epigenomics.com)

### About Epigenomics

Epigenomics is a molecular diagnostics company with a focus on the development of novel products for cancer. Using DNA methylation biomarkers, Epigenomics' tests on the market and in development aim at diagnosing cancer at an early stage before symptoms occur and thereby may reduce mortality from this dreaded disease.

Epigenomics' product portfolio contains the CE-marked IVD test Epi proColon, the world's first regulatory cleared molecular diagnostic test for the detection of colorectal cancer in blood that is based on the biomarker Septin9, and further proprietary DNA methylation biomarkers and IVD products at various stages of development for colorectal, lung and prostate cancer. For development and global commercialization of IVD test products, Epigenomics pursues a dual business strategy in which direct commercialization of proprietary diagnostic test products is combined with non-exclusive licensing to diagnostic industry players with broad customer access. Strategic diagnostics industry partners include Abbott Molecular, Sysmex Corporation, Quest Diagnostics Incorporated, and ARUP Laboratories, Inc. for diagnostics test products and services, and QIAGEN N.V. for sample preparation solutions and research products. The company is headquartered in Berlin, Germany, and has a wholly owned subsidiary, Epigenomics Inc., in Seattle, WA, USA. For more information, please visit Epigenomics' website at { [www.epigenomics.com](http://www.epigenomics.com) } [HYPERLINK]: <http://www.epigenomics.com/>

Epigenomics legal disclaimers. This communication expressly or implicitly contains certain forward-looking statements concerning Epigenomics AG and its business. Such statements involve certain known and unknown risks, uncertainties and other factors which could cause the actual results, financial condition, performance or achievements of Epigenomics AG to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Epigenomics AG is providing this communication as of this date and does not undertake to update any forward-looking statements contained herein as a result of new information, future events or otherwise.

The information contained in this communication does not constitute nor imply an offer to sell or transfer any product, and no product based on this technology is currently available for sale in the United States of America. The analytical and clinical performance characteristics of any product based on this technology which may be sold at some future time in the USA have not been established.

end of announcement

euro adhoc

-----  
inquiry note:

Further

Epigenomics AG  
Dr. Achim Plum  
Sen. VP Corporate Development  
Tel: +49 30 24345 368  
[achim.plum@epigenomics.com](mailto:achim.plum@epigenomics.com)

Branche: Biotechnology  
ISIN: DE000A0BVT96  
WKN: A0BVT9  
Index: Prime All Share, Technology All Share  
Börsen: Frankfurt / regulated dealing/prime standard  
Berlin / free trade  
Hamburg / free trade  
Stuttgart / free trade  
Düsseldorf / free trade  
München / free trade

Originaltext:

Epigenomics AG

ISIN:

DE000A1K0516

Pressemappe:

<http://www.presseportal.de/pm/38683/epigenomics-ag>

Pressemappe als RSS:

[http://presseportal.de/rss/pm\\_38683.rss2](http://presseportal.de/rss/pm_38683.rss2)